Sarepta therapeutics director Mayo sells $123k in shares

Director Stephen Mayo sold 7,239 Sarepta (NASDAQ: SRPT) shares on Mar 12, 2026 at $17.02 for $123,207 (now holds 1,765 shares), a sale disclosed as to cover tax obligations from RSU vesting. SRPT trades near $16.40, down ~84% from its 52-week high of $103.32, while analysts lifted targets—Mizuho $31 (Outperform), Jefferies $30 (Buy), Freedom Capital $25 (Buy)—citing updated sales/expense forecasts and conference data. Sarepta will present Phase 3 EMBARK data on delandistrogene moxeparvovec (up to 3 years post-infusion) and there is potential FDA discussions in Mar 2026 on Amondys/Vyondys, making the story a mix of severe past share decline and possible recovery catalysts from upcoming clinical/regulatory events.

Analysis

Sarepta’s upcoming durable efficacy readouts create classic binary optionality: a clean three‑year durability signal would materially derisk long‑term payer contracts and convert a narrative of reputational repair into multi‑year revenue compounding. Second‑order beneficiaries include contract manufacturers and specialty pharmacies that can demonstrate rapid scale and cold‑chain reliability; conversely, small CDMOs exposed to single‑source supply agreements would see order reallocation risk if Sarepta expands internal capacity.

Key catalyst timing is clustered—late‑breaking conference data followed by regulatory interactions and payer negotiations—so realization risk compresses into the next 3–12 months, with commercialization execution playing out over 12–36 months. Tail risks are not scientific only: persistent prescriber hesitation, pricing pushback from payers, or a manufacturing hold could keep upside latent and produce fast downside given the stock’s low liquidity/convexity.

The optimal trade is asymmetry: capture upside to a favorable regulatory/commercial inflection with limited downside. Use long‑dated, low‑cost optionality or equity with explicit hedges to buy time; avoid naked short exposure into the data window. Monitor two reversal signals that should trigger quick de‑risking: a clear divergence between caregiver‑reported benefit and objective endpoints, or public payor statements curtailing coverage on new label language.

Consensus underweights the pace at which durable gene therapy wins change payor math—if even 20–30% of eligible patients adopt within 24 months post‑label clarity, present valuations underappreciate multi‑year cashflows. That said, the market is correctly pricing binary execution risk; position sizes should reflect event risk and commercial friction, not base‑case optimism.

Key Decisions for Investors

• Buy SRPT Jan 2028 $25 LEAP calls (size 0.5–1.0% NAV): asymmetric upside if durability data and payer discourse go positive; max loss = premium paid; take 50% profits on 2x and trim to break even on 1.5x.
• Buy SRPT stock with a 6‑month protective put ~15% OTM (size 1% NAV): protects 1–2 upcoming catalyst windows while leaving upside intact; roll protection forward post‑catalyst if thesis intact.
• Sell shorter‑dated calls to finance LEAP exposure (covered/diagonal): sell 3–6 month calls ~25–35% OTM to reduce net premium and force a defined profit‑taking cadence into the conference and regulatory calendar.
• Reallocate tactically: reduce 0.5–1% NAV exposure to high‑beta tech names (e.g., SMCI/APP) and redeploy into the asymmetric SRPT constructs above—this replaces momentum beta with single‑asset binary upside while keeping overall portfolio volatility neutral.